Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy

Clinical Cancer Research

Volumn 16, Issue 4, 2010, Pages 1307-1314

  Lee, Dae Ho ^a   Park, Keunchil ^b   Kim, Joo Hang ^c   Lee, Jong Seok ^f   Shin, Sang Won ^d   Kang, Jin Hyoung ^e   Ahn, Myung Ju ^b   Ahn, Jin Seok ^b   Suh, Cheolwon ^a   Kim, Sang We ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ERLOTINIB; GEFITINIB; PLATINUM;

ADVANCED CANCER; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPIRATION PNEUMONIA; ASTHENIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRY SKIN; DYSPEPSIA; DYSPNEA; FEMALE; HEMOPTYSIS; HUMAN; INCIDENCE; INSOMNIA; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUROTOXICITY; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SEPTIC SHOCK; STOMATITIS; THORAX PAIN; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLATINUM COMPOUNDS; QUINAZOLINES; RETREATMENT; TAXOIDS; TIME FACTORS;

EID: 76749154617     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1903     Document Type: Article

References (15)

1. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
2. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 2003;290:2149-58.
3. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37.
4. Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006; 1:847-55.
5. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
6. Fossella FV, Devore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000;18:2354-62.
7. Kim ES, Hirsch V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-18.
8. Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26: 4244-52.
9. Bae NC, Chae NH, Lee MH, et al. EGFR, ERBB2 and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet 2007;173:107-13.
10. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23: 2493-501.
11. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500.
12. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361: 958-67.
13. Mok TS, Wu YL, THongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-57.
14. Park JO, Kim SW, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 2007;25:5233-39.
15. Ahn MJ, Park BB, Ahn JS, et al. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res 2008;14:3860-6.